Niki BioSolutions, Inc. (NASDAQ: NIKI) ("Niki" or the "Company"), a clinical-stage life sciences company focused on unmet medical needs and genomic and biomarker testing solutions, today announced that its wholly owned subsidiary, DiamiR Biosciences Corp. ("DiamiR"), will perform apolipoprotein E (APOE) genotyping on plasma samples from the Global Alzheimer’s Platform Foundation® ("GAP") Bio-Hermes-002 study cohort.

The APOE ε4 allele is the strongest known genetic risk factor for late-onset Alzheimer’s disease, and APOE genotype informs clinical trial design and enrollment as well as risk assessment for amyloid-related imaging abnormalities (ARIA) with anti-amyloid therapies. Genotyping directly from banked plasma adds genetic information to existing samples without additional blood draws.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.